Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

The aberrant c-Met activation has been implicated in a variety of human cancers for its critical role in tumor growth, metastasis and tumor angiogenesis. Thus, c-Met axis presents as an attractive therapeutic target. Notably, most of these c-Met inhibitors currently being evaluated in clinical trial...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Wang, Ying, Zhan, Zhengsheng, Jiang, Xifei, Peng, Xia, Shen, Yanyan, Chen, Fang, Ji, Yinchun, Liu, Weiren, Shi, Yinghong, Duan, Wenhu, Ding, Jian, Ai, Jing, Geng, Meiyu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5122374/
https://ncbi.nlm.nih.gov/pubmed/27191264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9349
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg